T Cell Non-Hodgkin Lymphoma

Cumulatively, these therapies illustrate both the progress and the ongoing challenges of biomarker-driven treatment in NHL, including resistance mechanisms, toxicity management, optimal therapeutic sequencing, and variability in evidence maturity across targeted strategies. While pirtobrutinib and brentuximab vedotin are supported by increasingly robust clinical evidence in selected lymphoma subtypes, the role of belinostat remains constrained by modest response rates and limited randomized data, underscoring the continued need for biomarker refinement and more precisely individualized therapeutic approaches in NHL precision medicine.

This report explores the clinical and histological manifestations of GMF, features distinguishing GMF from other granulomatous diseases, such as IGD, and the prognostic significance of distinguishing GMF from classic mycosis fungoides. We aimed to raise awareness among physicians regarding this rare disease and emphasize the characteristic histological features of GMF that can be confused with other types of mycosis fungoides.

Antibody screen acted as a whistleblower for an undiagnosed aggressive lymphoma. Thus, it will be prudent to look beyond the obvious in complex cases, and a detailed workup will help put together all parts of the jigsaw puzzle.

She received alectinib combined with CNS-directed chemotherapy and has remained in complete remission for 20 months on alectinib maintenance. These cases suggest that alectinib, combined with CNS-directed chemotherapy, is effective in both ALK-positive ALCL with CNS relapse and primary isolated CNS disease.

P1, N=20, Recruiting, Huda Salman | Trial completion date: Dec 2041 --> Dec 2042 | Trial primary completion date: Dec 2026 --> Dec 2027

To report a rare case of monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) presenting with acute gastrointestinal perforation and to describe the use of an exploratory regimen combining a BCL-2 inhibitor (Venetoclax) with CHOP chemotherapy, highlighting the diagnostic challenges and therapeutic considerations for this aggressive disease...Besides, the prolonged untreated interval observed in this patient highlights the potential biological heterogeneity of MEITL. While the observed complete metabolic remission is encouraging, this finding remains hypothesis-generating and requires validation in larger studies.

While fludarabine and cyclophosphamide (Flu/Cy) remain the standard LD regimen, bendamustine has emerged as a potential alternative due to its distinct immunomodulatory properties and more favorable toxicity profile. However, the current evidence is largely derived from retrospective and non-randomized studies. Prospective, comparative trials are warranted to validate these findings and to better define the optimal LD strategy across disease types and CAR-T platforms.

P2, N=35, Not yet recruiting, Peking University First Hospital

The patient was treated with brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone, following which the febrile episodes improved. This case illustrates an uncommon gastrointestinal-predominant presentation of ALK-negative systemic ALCL presenting as fever of unknown origin. This case underscores the importance of continued diagnostic reassessment and symptom-guided tissue acquisition when conventional staging studies are not initially diagnostic, particularly in patients with a history of indolent lymphoma.

After nivolumab discontinuation and transition to avelumab, the patient experienced complete metabolic resolution of cardiac involvement, improvement in cardiac biomarkers, and durable control of cutaneous lymphoma over more than 3 years of follow-up. This case highlights a temporal association between programmed cell death-1 blockade and atypical dissemination of cutaneous T-cell lymphoma, supported by biologic plausibility, and underscores a potential therapeutic distinction between programmed cell death-1 and programmed death ligand-1 inhibition in malignant T-cell disorders.

P=N/A, N=1000, Not yet recruiting, Ruijin Hospital